One study, performed using a subcutaneous or peritoneal SKOV3 ovarian cancer model targeting HER2 in immunodeficient mice, confirmed the anti-tumor effects of NIR-PIT from a reduction in tumor volume [34]. Here, ERBB2 is linked to neoplasm.